Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole

被引：0

作者：

C. Skedgel

D. Rayson

R. Dewar

T. Younis

机构：

[1] Dalhousie University,Department of Medicine, Centre for Clinical Research

[2] Cancer Care Nova Scotia,undefined

来源：

Breast Cancer Research and Treatment | 2007年 / 101卷

关键词：

Adjuvant hormonal therapy; Anastrozole; Aromatase inhibitors; Breast cancer; Cost-utility analysis; Exemestane; Tamoxifen;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：325 / 333

页数：8

共 50 条

[31] A RANDOMIZED TRIAL OF TAMOXIFEN VERSUS TAMOXIFEN WITH AMINOGLUTETHIMIDE IN POST-MENOPAUSAL WOMEN WITH ADVANCED BREAST-CANCER
MILSTED, R
HABESHAW, T
KAYE, S
SANGSTER, G
MACBETH, F
CAMPBELLFERGUSON, J
SMITH, D
CALMAN, K
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1985, 14 (03) : 272 - 273
[32] The effects of adjuvant anastrozole, exemestane, tamoxifen, and toremifene on serum lipids in postmenopausal women with breast cancer - a randomised study.
Kataja, V
Hietanen, P
Joensuu, H
Ala-Luhtala, T
Asola, R
Kokko, R
Holli, K
BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S156 - S156
[33] Comparison of the cost-effectiveness of upfront letrozole or anastrozole, or switched exemestane versus tamoxifen for early breast cancer in hormone receptor positive (HR+) postmenopausal women: the UK perspective.
Karnon, J.
Delea, T. E.
Kaura Meng, S.
di Trapani, F.
BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S229 - S229
[34] COST-UTILITY ANALYSIS OF DENOSUMAB VERSUS RALOXIFENE FOR TREATING OSTEOPOROSIS IN POST-MENOPAUSAL WOMEN IN THE UNITED STATES
Beaubrun, A. C.
Daugherty, J. B.
VALUE IN HEALTH, 2011, 14 (03) : A129 - A129
[35] The anastrozole, tamoxifen, alone or in combination (ATAC) adjuvant breast cancer trial in post-menopausal women: Regional variation in knowledge of hormone receptor status prior to randomisation into the trial. The ATAC Trialists' Group.
Howell, A
ANNALS OF ONCOLOGY, 2000, 11 : 20 - 20
[36] Exemestane after non-steroidal aromatase inhibitors for post-menopausal women with advanced breast cancer
Chin, Y. S.
Beresford, M. J.
Ravichandran, D.
Makris, A.
BREAST, 2007, 16 (04): : 436 - 439
[37] Exemestane after non-steroidal aromatase inhibitors for post-menopausal women with advanced breast cancer
不详
EJC SUPPLEMENTS, 2006, 4 (02): : 167 - 167
[38] Controversies in adjuvant endocrine therapy for pre- and post-menopausal women with breast cancer
Ciccarese, Mariangela
Lorusso, Vito
De Laurentis, Michele
EJC SUPPLEMENTS, 2008, 6 (14): : 4 - 9
[39] Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer
Cheng, Tsui Fen
Wang, Jung Der
Uen, Wu Ching
BMC CANCER, 2012, 12
[40] Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer
Tsui Fen Cheng
Jung Der Wang
Wu Ching Uen
BMC Cancer, 12

← 1 2 3 4 5 →